Clinical Trials Link
Primary Protocol Team Members
P1063 is a Phase I/II study of atorvastatin in HIV-infected participants ≥ 10 to < 24 years of age. The study is designed to evaluate the safety and efficacy (based on direct LDL-cholesterol levels) of escalating doses of atorvastatin in participants on a stable antiretroviral regimen. Participants are followed on atorvastatin for 48 weeks.